Effects of GSK v Teva Ripple after SCOTUS Denies Cert
May 23, 2023
By: Ross Blau
Life Sciences IP Review
Axinn associate Ross Blau co-authored the Life Sciences IP Review article, "Effects of GSK v Teva Ripple after SCOTUS Denies Cert."
Click here to access the publication. A subscription is required.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
AHLA Annual Meeting 2025
Speaking Engagement
Antitrust
SABA North America Annual Conference 2025
Speaking Engagement
Antitrust
Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
Webinar
Antitrust
NJSBA Annual Meeting and Convention 2025
Speaking Engagement
Intellectual Property
Hartford HealthCare Black and Red Gala 2025
Sponsorship
Antitrust
Informa CompLaw Antitrust West Coast Conference 2025
Speaking Engagement
Antitrust
AHLA Health Care Transactions Program 2025
Sponsorship
Antitrust
IAM Live: Auto IP USA 2025
Speaking Engagement
Intellectual Property
ACI 21st Annual Paragraph IV Conference
Speaking Engagement
Intellectual Property